Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
1,115 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04095273 | Study to Test How Well Patients With Advanced Solid Tumors Respond to Treatment With the Elimusertib in Combination With Pembrolizumab, to Find the Optimal Dose for Patients, How the Drug is Tolerated and the Way the Body Absorbs, Distributes and Discharges the Drug | completed | Phase 1 | 56 | BayerINDUSTRY | 5 | Apr 2, 2024 | clinicaltrials |
| NCT04901806 | Study of PBI-200 in Subjects With NTRK-Fusion-Positive Solid Tumors | terminated | Phase 1 | 29 | Pyramid BiosciencesINDUSTRY | 11 | Mar 28, 2024 |
| clinicaltrials |
| NCT01897571 | Study of Tazemetostat as Single Agent in Solid Tumors or B-cell Lymphomas and in Combination With Prednisolone in DLBCL | completed | Phase 1 / Phase 2 | 400 | Epizyme, Inc.INDUSTRY | 10 | Mar 26, 2024 | clinicaltrials |
| NCT04113616 | An Open-Label, Multicenter, Phase 1b/2 Study of the Safety and Efficacy of KRT-232 When Administered Alone and in Combination With Low-Dose Cytarabine (LDAC) or Decitabine in Patients With Acute Myeloid Leukemia (AML) | terminated | Phase 1 / Phase 2 | 70 | Kartos Therapeutics, Inc.INDUSTRY | 12 | Mar 22, 2024 | clinicaltrials |
| NCT01386619 | NK DLI in Patients After Human Leukocyte Antigen (HLA)-Haploidentical Hematopoietic Stem Cell Transplantation (HSCT) | completed | Phase 1 / Phase 2 | 15 | University Hospital, Basel, SwitzerlandOTHER | 2 | Mar 19, 2024 | clinicaltrials |
| NCT02632721 | A Trial to Find and Investigate a Safe Dose of BI 836858 in Combination With Decitabine for Patients With Acute Myeloid Leukemia (AML) | completed | Phase 1 / Phase 2 | 49 | Boehringer IngelheimINDUSTRY | 4 | Mar 19, 2024 | clinicaltrials |
| NCT02081378 | A Phase I Study of Oral Asciminib (ABL001) in Patients With CML or Ph+ ALL | completed | Phase 1 | 326 | Novartis PharmaceuticalsINDUSTRY | 10 | Mar 18, 2024 | clinicaltrials |
| NCT04069026 | A First-in-Humans Dose Finding Study for an Aryl Hydrocarbon Receptor Inhibitor (AhRi) in Patients With Advanced Cancer | completed | Phase 1 | 78 | BayerINDUSTRY | 5 | Mar 6, 2024 | clinicaltrials |
| NCT04540705 | A Study to Compare Bempegaldesleukin (BEMPEG: NKTR-214) Combined With Nivolumab and Tyrosine Kinase Inhibitor (TKI) to Nivolumab and TKI Alone in Participants With Previously Untreated Kidney Cancer That is Advanced or Has Spread(PIVOT IO 011) | completed | Phase 1 | 30 | Bristol-Myers SquibbINDUSTRY | 8 | Feb 28, 2024 | clinicaltrials |
| NCT02056756 | Carfilzomib In Combination With Bendamustine And Dexamethasone In Refractory Or Relapsed Multiple Myeloma | completed | Phase 1 / Phase 2 | 63 | Stichting European Myeloma NetworkNETWORK | 2 | Feb 20, 2024 | clinicaltrials |
| NCT03516214 | EGF816 and Trametinib in Patients With Non-small Cell Lung Cancer Harboring Activating EGFR Mutations(EATON) | completed | Phase 1 | 18 | University of CologneOTHER | 2 | Feb 15, 2024 | clinicaltrials |
| NCT05641324 | A Study of ANV419 Alone or in Combination With Approved Treatments in Patients With Multiple Myeloma (OMNIA-2) | terminated | Phase 1 | 4 | Anaveon AGINDUSTRY | 5 | Feb 12, 2024 | clinicaltrials |
| NCT03838042 | INFORM2 Study Uses Nivolumab and Entinostat in Children and Adolescents With High-risk Refractory Malignancies | recruiting | Phase 1 / Phase 2 | 91 | University Hospital HeidelbergOTHER | 7 | Feb 7, 2024 | clinicaltrials |
| NCT05430555 | A Phase 1/ 2, First-in-Human, Open-Label, Accelerated-Titration, Two-Part Clinical Trial of TK-8001 in Patients With HLA-A*02:01 Genotype and Advanced-Stage/ Metastatic MAGE-A1+ Solid Tumors(IMAG1NE) | terminated | Phase 1 / Phase 2 | 23 | T-knife GmbHINDUSTRY | 5 | Feb 7, 2024 | clinicaltrials |
| NCT04046614 | Feasibility and Safety of Nintedanib in Combination With Nivolumab in Pretreated Patients With Advanced or Metastatic NSCLC of Adenocarcinoma Histology(NintNivo) | completed | Phase 1 / Phase 2 | 56 | AIO-Studien-gGmbHOTHER | 1 | Feb 6, 2024 | clinicaltrials |
| NCT02152956 | Flotetuzumab in Primary Induction Failure (PIF) or Early Relapse (ER) Acute Myeloid Leukemia (AML)(VOYAGE) | terminated | Phase 1 / Phase 2 | 244 | MacroGenicsINDUSTRY | 8 | Jan 30, 2024 | clinicaltrials |
| NCT02367456 | A Combination Study of PF-04449913 (Glasdegib) and Azacitidine In Untreated MDS, AML and CMML Patients(BRIGHT 1012) | completed | Phase 1 | 73 | PfizerINDUSTRY | 6 | Jan 19, 2024 | clinicaltrials |
| NCT02658968 | Study of Betalutin for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma (LYMRIT-37-05) | completed | Phase 1 | 18 | Nordic NanovectorINDUSTRY | 5 | Jan 16, 2024 | clinicaltrials |
| NCT03422679 | Study of CB-103 in Adult Patients With Advanced or Metastatic Solid Tumours and Haematological Malignancies | terminated | Phase 1 / Phase 2 | 79 | Cellestia Biotech AGINDUSTRY | 6 | Jan 16, 2024 | clinicaltrials |
| NCT02789254 | FLYSYN in MRD Positive AML(FLYSYN-101) | completed | Phase 1 / Phase 2 | 31 | Synimmune GmbHINDUSTRY | 1 | Dec 28, 2023 | clinicaltrials |
| NCT02571036 | A Safety, Tolerability and PK Study of DCC-2618 in Patients With Advanced Malignancies | completed | Phase 1 | 282 | Deciphera Pharmaceuticals, LLCINDUSTRY | 6 | Dec 13, 2023 | clinicaltrials |
| NCT03559413 | Patient-individualized Peptide Vaccination Based on Tumor-specific Mutations in Children and Young Adults With Primary/Relapsed ALL | completed | Phase 1 / Phase 2 | 30 | University Children's Hospital TuebingenOTHER | 1 | Dec 4, 2023 | clinicaltrials |
| NCT02733042 | A Study to Determine Dose, Safety, and Efficacy of Durvalumab as Monotherapy and in Combination Therapy in Subjects With Lymphoma or Chronic Lymphocytic Leukemia(FUSION NHL 001) | completed | Phase 1 / Phase 2 | 106 | CelgeneINDUSTRY | 7 | Nov 18, 2023 | clinicaltrials |
| NCT02488759 | An Investigational Immuno-therapy Study to Investigate the Safety and Effectiveness of Nivolumab, and Nivolumab Combination Therapy in Virus-associated Tumors(CheckMate358) | completed | Phase 1 / Phase 2 | 578 | Bristol-Myers SquibbINDUSTRY | 11 | Nov 13, 2023 | clinicaltrials |
| NCT04721301 | Ipilimumab, Maraviroc and Nivolumab in Advanced Metastatic Colorectal and Pancreatic Cancer the LUMINESCENCE Trial | completed | Phase 1 | 50 | University Hospital HeidelbergOTHER | 1 | Oct 17, 2023 | clinicaltrials |
| NCT04045613 | Derazantinib and Atezolizumab in Patients With Urothelial Cancer(FIDES-02) | completed | Phase 1 / Phase 2 | 95 | Basilea PharmaceuticaINDUSTRY | 14 | Oct 13, 2023 | clinicaltrials |
| NCT02957019 | A Phase I/II Study of the Tumor-targeting Human L19-IL2 Monoclonal Antibody-cytokine Fusion Protein in Combination With Rituximab in Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL) | terminated | Phase 1 / Phase 2 | 6 | Philogen S.p.A.INDUSTRY | 1 | Oct 10, 2023 | clinicaltrials |
| NCT02685826 | A Study of Durvalumab in Combination With Lenalidomide With and Without Dexamethasone in Adults With Newly Diagnosed Multiple Myeloma | completed | Phase 1 / Phase 2 | 56 | CelgeneINDUSTRY | 8 | Oct 6, 2023 | clinicaltrials |
| NCT00292045 | Immunization With NY-ESO-1 Protein Combined With CpG 7909 in Patients With Prostate Cancer | completed | Phase 1 | 15 | Ludwig Institute for Cancer ResearchOTHER | 2 | Oct 4, 2023 | clinicaltrials |
| NCT03158389 | NCT Neuro Master Match - N²M² (NOA-20)(N²M²) | completed | Phase 1 / Phase 2 | 228 | University Hospital HeidelbergOTHER | 1 | Sep 28, 2023 | clinicaltrials |
| NCT04145700 | CAMPFIRE: A Study of Ramucirumab (LY3009806) in Children and Young Adults With Synovial Sarcoma | terminated | Phase 1 / Phase 2 | 23 | Eli Lilly and CompanyINDUSTRY | 10 | Sep 13, 2023 | clinicaltrials |
| NCT02658890 | An Investigational Immuno-therapy Study of BMS-986205 Given in Combination With Nivolumab and in Combination With Both Nivolumab and Ipilimumab in Cancers That Are Advanced or Have Spread | completed | Phase 1 / Phase 2 | 627 | Bristol-Myers SquibbINDUSTRY | 11 | Aug 28, 2023 | clinicaltrials |
| NCT04845841 | Comparison of the Extent to Which the Drug Given as Two Different Capsule Sizes Becomes Available to the Body | completed | Phase 1 | 16 | BayerINDUSTRY | 1 | Aug 9, 2023 | clinicaltrials |
| NCT03492437 | Effect of Tepotinib on the PK of the P-gp Substrate Dabigatran Etexilate | completed | Phase 1 | 20 | Merck KGaA, Darmstadt, GermanyINDUSTRY | 1 | Aug 7, 2023 | clinicaltrials |
| NCT03531762 | Effect of a Proton Pump Inhibitor on the PK of Tepotinib | completed | Phase 1 | 12 | Merck KGaA, Darmstadt, GermanyINDUSTRY | 1 | Jul 28, 2023 | clinicaltrials |
| NCT03347292 | Regorafenib Plus Pembrolizumab in First Line Systemic Treatment of HCC | completed | Phase 1 | 58 | BayerINDUSTRY | 2 | Jul 25, 2023 | clinicaltrials |
| NCT02432274 | Study of Lenvatinib in Children and Adolescents With Refractory or Relapsed Solid Malignancies and Young Adults With Osteosarcoma | completed | Phase 1 / Phase 2 | 117 | Eisai LimitedINDUSTRY | 6 | Jul 11, 2023 | clinicaltrials |
| NCT03927573 | Study With Bispecific Antibody Engaging T-cells, in Patients With Progressive Cancer Diseases With Positive PSCA Marker | terminated | Phase 1 | 23 | AvenCell Europe GmbHINDUSTRY | 1 | Jul 10, 2023 | clinicaltrials |
| NCT02795429 | Phase Ib/II Study of INC280 + PDR001 or PDR001 Single Agent in Advanced HCC | completed | Phase 1 / Phase 2 | 89 | Novartis PharmaceuticalsINDUSTRY | 8 | Jul 3, 2023 | clinicaltrials |
| NCT01126736 | Eribulin Mesylate Administered in Combination With Pemetrexed Versus Pemetrexed Alone as Second Line Therapy in Patients With Stage IIIB or IV Nonsquamous Non Small Cell Lung Cancer | completed | Phase 1 / Phase 2 | 98 | Eisai Inc.INDUSTRY | 5 | Jun 22, 2023 | clinicaltrials |
| NCT02335944 | Study of Safety and Efficacy of EGFR-TKI EGF816 in Combination With cMET Inhibitor INC280 in Adult Patients With EGFR Mutated Non Small Cell Lung Cancer. | terminated | Phase 1 / Phase 2 | 177 | Novartis PharmaceuticalsINDUSTRY | 11 | Jun 18, 2023 | clinicaltrials |
| NCT00481091 | A Study of ABT-263 in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia | completed | Phase 1 / Phase 2 | 60 | AbbVieINDUSTRY | 4 | Jun 13, 2023 | clinicaltrials |
| NCT04471415 | Study to Investigate DRP-104 in Adults With Advanced Solid Tumors | terminated | Phase 1 / Phase 2 | 61 | Dracen Pharmaceuticals, Inc.INDUSTRY | 5 | Jun 12, 2023 | clinicaltrials |
Data updated 23 days agoSource updated unknownsource: clinicaltrials